News

Inside the deal: Roche and Zealand Pharma's $5.3 billion obesity drug gambit
The ballooning obesity drug market may have a new contender after Roche struck a $5.3 billion deal to develop Danish ...
The GLP-1 Saga Continues, And How
Keeping up with the GLP-1 area is a full-time job by itself. First off, you have the recent development that these drugs are ...
CVS Health Excludes Zepbound: Why Eli Lilly's 11%+ Drop Looks Overdone
Eli Lilly and Company's stock dropped 11% after CVS's Zepbound exclusion, but analysts see a mispricing opportunity. Click ...
Eli Lilly Stock Drops as Lowered Profit Outlook Outweighs Solid Q1 Results
Shares of Eli Lilly fell sharply Thursday morning after the pharmaceutical giant's lowered profit projections outweighed ...
Benzinga.com3d
Eli Lilly Stock Short Interest Report | NYSE:LLY | Benzinga
Short interest in Eli Lilly and Co (NYSE:LLY) decreased during the last reporting period, falling from 7.02M to 6.43M. This put 0.81% of the company's publicly available shares short. Short ...
Transneural Therapeutics Appoints CNS Drug Development Expert, Mark A. Demitrack, MD, as Chief Research and Development Officer
Transneural Therapeutics, Inc. (Transneural), a preclinical-stage biotechnology company aiming to transform the treatment of ...